- Home
- ARTV
as 09-18-2024 4:00pm EST
Stocks
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 232.8M | IPO Year: | 2024 |
| Target Price: | $21.25 | AVG Volume (30 days): | 79.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -40.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.71 - $16.00 | Next Earning Date: | 08-29-2024 |
| Revenue: | $29,256,000 | Revenue Growth: | 493.31% |
| Revenue Growth (this year): | -98.81% | Revenue Growth (next year): | N/A |
Latest ARTIVA BIOTHERAPEUTICS INC News
ARTV Breaking Stock News: Dive into ARTV Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference
GlobeNewswire
20 days ago
Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Simply Wall St.
2 months ago
Is Artiva Biotherapeutics (NASDAQ:ARTV) In A Good Position To Deliver On Growth Plans?
Compare ARTV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARTV ARTIVA BIOTHERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.